JP2013536233A5 - - Google Patents

Download PDF

Info

Publication number
JP2013536233A5
JP2013536233A5 JP2013526063A JP2013526063A JP2013536233A5 JP 2013536233 A5 JP2013536233 A5 JP 2013536233A5 JP 2013526063 A JP2013526063 A JP 2013526063A JP 2013526063 A JP2013526063 A JP 2013526063A JP 2013536233 A5 JP2013536233 A5 JP 2013536233A5
Authority
JP
Japan
Prior art keywords
piperazinyl
phenyl
methyl
trifluoro
propanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013526063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536233A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048596 external-priority patent/WO2012027261A1/en
Publication of JP2013536233A publication Critical patent/JP2013536233A/ja
Publication of JP2013536233A5 publication Critical patent/JP2013536233A5/ja
Pending legal-status Critical Current

Links

JP2013526063A 2010-08-23 2011-08-22 グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用の化合物 Pending JP2013536233A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37614110P 2010-08-23 2010-08-23
US61/376,141 2010-08-23
US201161492634P 2011-06-02 2011-06-02
US61/492,634 2011-06-02
PCT/US2011/048596 WO2012027261A1 (en) 2010-08-23 2011-08-22 Sulfonylpiperazine derivatives that interact with glucokinase regulatory protein for the treatment of diabetes

Publications (2)

Publication Number Publication Date
JP2013536233A JP2013536233A (ja) 2013-09-19
JP2013536233A5 true JP2013536233A5 (enExample) 2014-05-15

Family

ID=44840531

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013526063A Pending JP2013536233A (ja) 2010-08-23 2011-08-22 グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用の化合物

Country Status (10)

Country Link
US (1) US8431563B2 (enExample)
EP (1) EP2609081A1 (enExample)
JP (1) JP2013536233A (enExample)
AR (1) AR082534A1 (enExample)
AU (1) AU2011293584B2 (enExample)
CA (1) CA2808590A1 (enExample)
MX (1) MX2013002208A (enExample)
TW (1) TW201238941A (enExample)
UY (1) UY33568A (enExample)
WO (1) WO2012027261A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013123444A1 (en) * 2012-02-17 2013-08-22 Amgen Inc. Sulfonyl compounds that interact with glucokinase regulatory protein
WO2013173382A1 (en) * 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
WO2014035872A1 (en) * 2012-08-27 2014-03-06 Amgen Inc. Tricyclic alkynes that interact with glucokinase regulatory protein
JP6102637B2 (ja) * 2013-08-22 2017-03-29 Jsr株式会社 芳香族ジハライド化合物、重合体、重合体組成物及び成形体
CN108912020B (zh) * 2018-06-05 2021-05-28 上海博志研新药物技术有限公司 奥当卡替及其中间体的制备方法
US20240124400A1 (en) * 2019-10-11 2024-04-18 Duke University Lpxh targeting compounds, compositions thereof, and methods of making and using the same
CN114349711B (zh) * 2022-02-28 2023-08-15 四川依维欣医药科技有限公司 一种(R)-1-Boc-3-羟甲基哌嗪的合成方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9821199D0 (en) 1998-09-30 1998-11-25 Glaxo Group Ltd Chemical compounds
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
PL377091A1 (pl) 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
EP1663193B1 (en) * 2003-09-12 2012-04-04 Merck Serono SA Sulfonamide derivatives for the treatment of diabetes
FR2874011B1 (fr) 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique
GB0505084D0 (en) 2005-03-11 2005-04-20 Glaxo Group Ltd Compounds
JP2009506988A (ja) 2005-08-19 2009-02-19 エラン ファーマシューティカルズ,インコーポレイテッド ガンマセクレターゼの架橋n−環状スルホンアミド阻害剤
CA2632027A1 (en) * 2005-12-14 2007-06-21 Amgen Inc. Diaza heterocyclic sulfonamide derivatives and their uses
AU2007231594A1 (en) * 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
BRPI0816881A2 (pt) 2007-09-21 2015-03-17 Array Biopharma Inc Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
JPWO2009096198A1 (ja) * 2008-02-01 2011-05-26 一般社団法人ファルマIp 新規ビアリール誘導体
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
FR2935380B1 (fr) 2008-08-29 2010-09-10 Galderma Res & Dev Nouveaux composes hexafluoro-2-biphenyl-isopropanol, modulateurs des recepteurs de type lxrs, leur procede de preparation et leur application comme medicaments en medecine humaine ou veterinaire ainsi qu'en cosmetique.
MX2011002705A (es) 2008-09-11 2011-09-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso.
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof

Similar Documents

Publication Publication Date Title
JP2013536233A5 (enExample)
US11905283B2 (en) Compounds and compositions for inhibiting the activity of SHP2
US11591336B2 (en) Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
US10975080B2 (en) Compounds and compositions for inhibiting the activity of SHP2
JP2007509141A5 (enExample)
US20250018049A1 (en) Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
JP2020531498A5 (enExample)
CN103261202B (zh) 作为腺苷受体拮抗剂的稠合三环化合物
JP2012522748A5 (enExample)
CN101263130A (zh) 2-苯胺-4-芳基取代的噻唑衍生物
JP2017524028A (ja) 薬剤としてのrip1キナーゼ阻害剤である複素環式アミド
JP2018135350A (ja) 炎症性障害の治療のための化合物及びその医薬組成物
CN103096718A (zh) 可溶性鸟苷酸环化酶活化剂
JP2022031915A (ja) Fshdの治療のためにdux4および下流遺伝子発現を低減するp38キナーゼ阻害剤
JP2019536785A5 (enExample)
US10072003B2 (en) Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use
JP2012532931A5 (enExample)
JP2007529484A5 (enExample)
US20150344490A1 (en) Heteroaromatic Compounds and their Use as Dopamine D1 Ligands
KR20170094263A (ko) Nadph 옥시다제 억제제인 아미도 티아디아졸 유도체
JP6893516B2 (ja) 3−((ヘテロ−)アリール)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
TW201321353A (zh) 胺基甲酸酯/尿素衍生物
JP2017523223A5 (enExample)
EA034904B1 (ru) Производные 3-(карбоксиметил)-8-амино-2-оксо-1,3-диазаспиро-[4.5]-декана
CN114258393A (zh) 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途